Related references
Note: Only part of the references are listed.Results of the First Phase 1 Clinical Trial of the HER-2/neu Peptide (GP2) Vaccine in Disease-Free Breast Cancer Patients
Mark G. Carmichael et al.
CANCER (2010)
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Linda C. Benavides et al.
CLINICAL CANCER RESEARCH (2009)
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence - From US Military Cancer Institute clinical trials group study I-01 and I-02
Jarrod P. Holmes et al.
CANCER (2008)
Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors
Hyun-Il Cho et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients:: US military cancer institute clinical trials group study I-01 and I-02
George E. Peoples et al.
CLINICAL CANCER RESEARCH (2008)
Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/neu peptide (AE37) vaccine
Jarrod P. Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Toll-like receptor ligands energize peptide vaccines through multiple paths
Esteban Celis
CANCER RESEARCH (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Laboratory analysis of T-cell immunity
KL Knutson et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
Peptide and dendritic cell vaccines
CL Slingluff et al.
CLINICAL CANCER RESEARCH (2006)
Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer
EA Mittendorf et al.
SURGERY (2006)
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
GE Peoples et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients
MT Hueman et al.
CLINICAL CANCER RESEARCH (2005)
Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the li-key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope
NL Kallinteris et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
D Avigan et al.
CLINICAL CANCER RESEARCH (2004)
Direct measurement of peptide-specific CD8C T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients
MM Woll et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer
ME Gillogly et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
ML Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide
RE Humphreys et al.
VACCINE (2000)
Share Paper
